Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging

World Journal of Gastroenterology

Volumn 20, Issue 13, 2014, Pages 3431-3442

  Saludes, Verónica ^a,b   González, Victoria ^a,b,c   Planas, Ramon ^a,d   Matas, Lurdes ^a,b   Ausina, Vicente ^e   Martró, Elisa ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Centre for Epidemiological Studies on HIV STI in Catalonia (CEEISCAT) ICO   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diagnosis; Hepatic fibrosis staging; Hepatitis C virus; Hepatitis C virus genotyping; Hepatitis C virus RNA quantification; Real time polymerase chain reaction; Serology

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA;

ANALYZER; ANTIBODY DETECTION; ARTICLE; DISEASE SEVERITY; ELASTOGRAPHY; END STAGE LIVER DISEASE; GENOTYPING TECHNIQUE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOBLOTTING; INFECTION CONTROL; LIVER BIOPSY; LIVER FIBROSIS; META ANALYSIS (TOPIC); NON INVASIVE PROCEDURE; POINT OF CARE TESTING; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEROLOGY; STAGING; BIOPSY; BLOOD; FIBROSIS; GENOTYPE; HEPACIVIRUS; HOSPITAL INFORMATION SYSTEM; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; VIROLOGY;

BIOPSY; COMMUNICABLE DISEASE CONTROL; FIBROSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOBLOTTING; LIVER; LIVER CIRRHOSIS; POINT-OF-CARE SYSTEMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84897485815     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i13.3431     Document Type: Article

References (96)

1. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938 [PMID: 16107832 DOI: 10.1038/nature]
2. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085 DOI: 10.1002/ hep.20819]
3. Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis C virus. In: Tang H, editor. Hepatitis C: Methods and Protocols. Totowa: Humana Press, 2009: 33-53 [DOI: 10.1007/978-1-59745-394-3_4]
4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321 DOI: 10.1038/nrgastro. 2013.107]
5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
6. World Health Organization. Hepatitis C: WHO Fact Sheet No. 164. [updated 2012 Jul; cited 2013 Apr]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
8. Alborino F, Burighel A, Tiller FW, van Helden J, Gabriel C, Raineri A, Catapano R, Stekel H. Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. Med Microbiol Immunol 2011; 200: 77-83 [PMID: 20865278 DOI: 10.1007/s00430-010-0171-0]
9. Ismail N, Fish GE, Smith MB. Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J Clin Microbiol 2004; 42: 610-617 [PMID: 14766824 DOI: 10.1128/JCM.42.2.610-617.2004]
10. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol 2005; 34: 97-103 [PMID: 16122974 DOI: 10.1016/j.jcv.2005.08.001]
11. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002 [PMID: 15934999 DOI: 10.1111/j.1537-2995.2005.04390.x]
12. Zelin J, Garrett N, Saunders J, Warburton F, Anderson J, Moir K, Symonds M, Estcourt C. An evaluation of the performance of OraQuick ADVANCE Rapid HIV-1/2 Test in a high-risk population attending genitourinary medicine clinics in East London, UK. Int J STD AIDS 2008; 19: 665-667 [PMID: 18824617 DOI: 10.1258/ijsa.2008.008132]
13. Branson B. Current HIV epidemiology and revised recommendations for HIV testing in health-care settings. J Med Virol 2007; 79 Suppl 1: S6-S10 [PMID: 17874432 DOI: 10.1002/ jmv.20972]
14. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 558-566 [PMID: 23070489 DOI: 10.7326/0003-4819 -157-8-201210160-00006]
15. Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204: 825-831 [PMID: 21849279 DOI: 10.1093/infdis/jir422]
16. Smith BD, Teshale E, Jewett A, Weinbaum CM, Neaigus A, Hagan H, Jenness SM, Melville SK, Burt R, Thiede H, Al-Tayyib A, Pannala PR, Miles IW, Oster AM, Smith A, Finlayson T, Bowles KE, Dinenno EA. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53: 780-786 [PMID: 21921221 DOI: 10.1093/cid/cir499]
17. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011; 172: 27-31 [PMID: 21182871 DOI: 10.1016/j.jviromet.2010.12.009]
18. Pai NP, Sollis K, Peeling RW. Rapid hepatitis C tests: better than the gold standard? Expert Rev Mol Diagn 2013; 13: 221-223 [PMID: 23570397 DOI: 10.1586/erm.13.13]
19. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: 211-218 [PMID: 12085367 DOI: 10.1053/jhep.2002.34130]
20. Park Y, Lee JH, Kim BS, Kim do Y, Han KH, Kim HS. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010; 48: 2253-2256 [PMID: 20351215 DOI: 10.1128/JCM.01856-09]
21. Descamps V, Op de Beeck A, Plassart C, Brochot E, François C, Helle F, Adler M, Bourgeois N, Degré D, Duverlie G, Castelain S. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 2012; 50: 465-468 [PMID: 22162563 DOI: 10.1128/JCM.06503-11]
22. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009; 157: 8-14 [PMID: 19135481 DOI: 10.1016/ j.jviromet.2008.12.009]
23. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46: 210-215 [PMID: 19766055 DOI: 10.1016/j.jcv.2009.08.014]
24. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: 1802-1808 [PMID: 10325327]
25. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010; 48: 18-21 [PMID: 20233674 DOI: 10.1016/ j.jcv.2010.02.012]
26. González V, Padilla E, Diago M, Giménez MD, Solà R, Matas L, Montoliu S, Morillas RM, Pérez C, Planas R. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. J Viral Hepat 2005; 12: 481-487 [PMID: 16108762 DOI: 10.1111/j.1365-2893.2005.00628.x]
27. Buti M, Mendez C, Schaper M, Sauleda S, Valdes A, Rodriguez- Frias F, Jardi R, Esteban R. Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2004; 40: 527-532 [PMID: 15123370 DOI: 10.1016/j.jhep.2003.11.026]
28. Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012; 55: 17-22 [PMID: 22698697 DOI: 10.1016/ j.jcv.2012.05.008]
29. Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant- Delmas A, Maniez-Montreuil M, Gallian P, Levayer T, Morel P, Simon N. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-3883 [PMID: 16081925 DOI: 10.1128/ JCM.43.8.3877-3883.2005]
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
31. Orlent H, Deltenre P, Francque S, Laleman W, Moreno C, Bourgeois S, Colle I, Delwaide J, De Maeght S, Mulkay JP, Stärkel P, Reynaert H. Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors. Acta Gastroenterol Belg 2012; 75: 245-259 [PMID: 22870791]
32. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011; 17: 116-121 [PMID: 21054664]
33. Chevaliez S, Bouvier-Alias M, Rodriguez C, Soulier A, Poveda JD, Pawlotsky JM. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol 2013; 51: 1078-1082 [PMID: 23325825 DOI: 10.1128/JCM.02004-12]
34. Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, Sizmann D, Cobb B, Sarrazin C. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013; 51: 571-577 [PMID: 23241371 DOI: 10.1128/ JCM.01784-12]
35. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011; 52: 133-137 [PMID: 21803650 DOI: 10.1016/ j.jcv.2011.07.007]
36. Drexler JF, Reber U, Wuttkopf A, Eis-Hübinger AM, Drosten C. Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens. J Clin Microbiol 2012; 50: 2114-2117 [PMID: 22403428 DOI: 10.1128/JCM.05874-11]
37. Paba P, Fabeni L, Perno CF, Ciotti M. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay. J Virol Methods 2012; 179: 77-80 [PMID: 22001273 DOI: 10.1016/ j.jviromet.2011.09.024]
38. Martinot-Peignoux M, Khiri H, Leclere L, Maylin S, Marcellin P, Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. J Clin Virol 2009; 46: 216-221 [PMID: 19748822 DOI: 10.1016/j.jcv.2009.08.011]
39. Pas S, Molenkamp R, Schinkel J, Rebers S, Copra C, Seven- Deniz S, Thamke D, de Knegt RJ, Haagmans BL, Schutten M. Performance evaluation of the new Roche cobas AmpliPrep/ cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol 2013; 51: 238-242 [PMID: 23152551 DOI: 10.1128/ jcm.01729-12]
40. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-1057 [PMID: 22095516 DOI: 10.1002/hep.24791]
41. Lontok E, Mani N, Harrington PR, Miller V. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis 2013; 56: 1466-1470 [PMID: 23362287 DOI: 10.1093/cid/ cit025]
42. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/ hep.22759]
43. Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Med Wkly 2012; 142: w13516 [PMID: 22367957 DOI: 10.4414/smw.2012.13516]
44. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 Suppl 2: 1-26 [PMID: 22404758 DOI: 10.1111/j.1365-2893.2012.01590.x]
45. Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112 [PMID: 17287328 DOI: 10.1128/jcm.02366-06]
46. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639 [PMID: 17680654 DOI: 10.1002/ hep.21781]
47. McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-2132 [PMID: 19273674 DOI: 10.1128/aac.01598-08]
48. Cento V, Landonio S, De Luca F, Di Maio VC, Micheli V, Mirabelli C, Niero F, Magni C, Rizzardini G, Perno CF, Ceccherini-Silberstein F. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir Ther 2013; 18: 645-648 [PMID: 23411358 DOI: 10.3851/imp2529]
49. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-1906 [PMID: 18400913 DOI: 10.1128/jcm.02390-07]
50. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145 [PMID: 17251399 DOI: 10.1128/jcm.01982-06]
51. Ciotti M, Marcuccilli F, Guenci T, Babakir-Mina M, Chiodo F, Favarato M, Perno CF. A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. J Virol Methods 2010; 167: 205-207 [PMID: 20362009 DOI: 10.1016/ j.jviromet.2010.03.017]
52. Shinol RC, Gale HB, Kan VL. Performance of the Abbott RealTime HCV Genotype II RUO assay. J Clin Microbiol 2012; 50: 3099-3101 [PMID: 22760043 DOI: 10.1128/jcm.01249-12]
53. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209 [PMID: 19997618 DOI: 10.1371/ journal.pone.0008209]
54. Lam TH, Cheng RS, Lai ST, Tsang TY, Cheng VC, Ho SL, Yam WC. Evaluation of in-house and commercial genotyping assays for molecular typing of hepatitis C virus in Hong Kong. Br J Biomed Sci 2010; 67: 82-85 [PMID: 20669764]
55. Larrat S, Poveda JD, Coudret C, Fusillier K, Magnat N, Signori-Schmuck A, Thibault V, Morand P. Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0. J Clin Microbiol 2013; 51: 2815-2821 [PMID: 23616453 DOI: 10.1128/jcm.00586-13]
56. González V, Gomes-Fernandes M, Bascuñana E, Casanovas S, Saludes V, Jordana-Lluch E, Matas L, Ausina V, Martró E. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J Clin Virol 2013; 58: 249-253 [PMID: 23731847 DOI: 10.1016/ j.jcv.2013.05.005]
57. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851 [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9]
58. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
59. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011; 193: 225-231 [PMID: 21803030 DOI: 10.1016/j.cbi.2011.07.001]
60. Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012; 56 Suppl 1: S66-S74 [PMID: 22300467 DOI: 10.1016/s0168-8278(12)60008-7]
61. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917 [PMID: 23675659 DOI: 10.1056/nejmra1213651]
62. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]
63. Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 656-663 [PMID: 21752038 DOI: 10.1111/j.1365-2036.2011.04765.x]
64. Grünhage F, Lammert F. Assessment of Hepatic Fibrosis and Steatosis. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology 2013 - A Clinical Textbook. Spanish: Flying Publisher, 2013: 336-349
65. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
66. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435 [DOI: 10.1007/ s12072-012-9342-y]
67. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010; 375: 1419-1420 [PMID: 20417845 DOI: 10.1016/s0140-6736(09)62195-4]
68. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultr asmedbio.2003.07.001]
69. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973 [PMID: 17255218 DOI: 10.1136/gut.2006.111302]
70. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-408 [PMID: 16020491 DOI: 10.1136/gut.2005.069153]
71. Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, Merrouche W, Couzigou P, de Ledinghen V. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-199, 1970-1979 [PMID: 21376047 DOI: 10.1053/j.gastro.2011.02.058]
72. Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835 [PMID: 20063276 DOI: 10.1002/hep23425]
73. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208 [PMID: 21898479 DOI: 10.1002/hep.24624]
74. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
75. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-2600 [PMID: 17850410 DOI: 10.1111/ j.1572-0241.2007.01466.x]
76. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a metaanalysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659 [PMID: 21146892 DOI: 10.1016/j.jhep.2010.07.033]
77. Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M, Gazzard B, Nelson M. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-219 [PMID: 19745758 DOI: 10.1097/MCG.0b013e3181b4af1f]
78. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and metaanalysis. Clin Gastroenterol Hepatol 2007; 5: 1214-1220 [PMID: 17916549 DOI: 10.1016/j.cgh.2007.07.020]
79. Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis crónica C (VHC) en pacientes monoinfectados. Agencia Española de Medicamentos y Productos Sanitarios. Available from: URL: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-VHC-monoinfectados_ 28-02-12.pdf
80. Carrión JA, Navasa M, Buti M, Torras X, Xiol X, Vergara M, Planas R, Solà R, Forns X. Document de posicionalment sobre la utilitat diagnòstica del Fibroscan®. Available from: URL: http://asscat-hepatitis.org/wp-content/uploads/consens_fibroscan-societat-catalana-de-digestologia.pdf
81. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferaseto- platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736 [PMID: 21319189 DOI: 10.1002/hep.24105]
82. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert- Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40 [PMID: 17937811 DOI: 10.1186/1471-230X-7-40]
83. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Penaranda G, Bréchot MC, Trocme C, Calès P. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376 [PMID: 18655779 DOI: 10.1016/j.clinbiochem.2008.06.020]
84. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013; 159: 372 [PMID: 24026329 DOI: 10.7326/0003-4819-159-5-201309030-00021]
85. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827 [PMID: 19291784 DOI: 10.1002/hep.22859]
86. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350 [PMID: 15685546 DOI: 10.1053/j.gastro.2004.11.018]
87. World Health Organization. Prevention & Control of Viral Hepatitis Infection: Framework for Global Action. 2012. Available from: URL: http://who.int/csr/disease/hepatitis/ GHP_Framework_En.pdf
88. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713 [PMID: 15578508 DOI: 10.1053/j.gastro.2004.08.052]
89. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-279 [PMID: 15046217 DOI: 10.1111/ j.1572-0241.2004.04055.x]
90. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-942 [PMID: 15582126 DOI: 10.1016/j.jhep.2004.08.008]
91. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
92. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-739 [PMID: 3135226]
93. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]
94. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873 [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389]
95. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-1381 [PMID: 16317693 DOI: 10.1002/hep.20935]
96. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6]